Variant-Stratified ALK Inhibitor Selection in EML4-ALK Lung Cancer

This narrative review synthesizes EML4-ALK variant biology, resistance mechanisms, and a proposed risk-stratified treatment algorithm that oncology pharmacists can apply to inhibitor selection and monitoring.

📅 Journal publication: Jan-Dec 2026 (online Jun 26, 2026) · Last updated: Jul 30, 2026

crizotinibalectinibbrigatinibceritiniblorlatinibiruplinalkibALK inhibitorsALK-TKIEML4-ALKNSCLCprotein degradersPROTACctDNAliquid biopsynarrative reviewprecision oncology Oncology Pharmacy

Background Information

EML4-ALK fusion: A precision target in NSCLC fraught with resistance challenges.

EML4-ALK fusion in NSCLC represents a significant target for precision oncology, where targeted therapies can enhance patient outcomes. ALK inhibitors are effective against EML4-ALK mutations; however, drug resistance limits long-term success. Continuous tumor monitoring and adaptive treatment strategies are crucial to manage resistance and optimize treatment in EML4-ALK-positive NSCLC. Effective management of EML4-ALK-positive NSCLC requires vigilant monitoring and adaptive therapy strategies due to drug resistance.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Li S, Bao L, Zhou D, Li D

Citation: Li S, Bao L, Zhou D, et al. EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies. Technology in cancer research & treatment. 2026;25:15330338261457490. doi:10.1177/15330338261457490

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.